Developmental Research Program

发展研究计划

• 批准号: 8389749
• 负责人: shelton Earp
• 金额: $ 9.83万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-05 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8389749
• 关键词: Advocate; Applications Grants; Award; Breast; Budgets; Cancer Center; Cancer Control; Cancer Research Project; Clinical; Clinical Trials; Commit; Consultations; Development; Evaluation; Expenditure; Extramural Activities; Funding; Grant; Incidence; Leadership; Malignant Neoplasms; Mission; Monitor; Morbidity - disease rate; National Institute of Environmental Health Sciences; Outcome; Peer Review; Population; Process; Program Research Project Grants; Public Health; Publications; Published Comment; Reporting; Research; Research Personnel; Research Project Grants; Scientist; Translational Research; Universities; Work; anticancer research; base; cancer prevention; experience; malignant breast neoplasm; mortality; novel; programs; technology development

Now in its 20th year, the UNC Breast Cancer SPORE's Developmental Research Program (DRP) continues to promote novel translational breast cancer research. The Program includes mechanisms for stimulating grant applications, evaluating proposals, selecting projects, and monitoring progress. Drs. Lisa Carey and Charles Perou, SPORE overall co-directors and leaders of the UNC Lineberger's Breast Cancer Research Program, oversee the DRP mechanisms for identification, evaluation, selection, and monitoring. Application mechanisms include Cancer Center-wide competitive awards and rapidly emerging opportunities. Evaluation and selection processes include independent peer review and consultation with the SPORE Executive Committee and senior leadership and external advisors (including advocates). The SPORE Director/PI (Dr. Earp), with input from the Co-Directors/Co-PIs (Carey, Perou) and the Executive Committee, makes final decisions regarding selection and budget. The DRP has continued to be effective. During the past six years (Years 14 - 19), the program funded 17 projects, bringing the overall total to 61 projects since the SPORE inception in 1992. As in past years, DRP projects have led to full-fledged SPORE projects and independently funded projects as well as publications. For example, three of the five projects proposed for Year 20-24 SPORE support have involved DRP projects from the last four years: (1) Project 5 (Johnson, Earp) is building upon DRP project #54 (Johnson); (2) Project 4 (Troester, Amos) grew directly out of DRP project #53 (Troester); and (3) Project 2 (Serody, Dees) has been developed through DRF project #51 (Serody). In addition. Projects 1 (Millikan, Carey, Lin) and 3 (Perou, Carey) were originally based on work that was initiated DRP in earlier cycles. Among 17 DRP projects supported the last six years, six have just begun. Among the eleven more mature projects, all are progressing with publications, full projects or extramural funding. Ten have resulted in extramural funding (including three NCI R01s, two NCI K23, two Komen grants, one DoD Idea Award, one NIEHS U01, and one Stand Up to Cancer Award). Eight projects have produced publications, and three have supported development of clinical trials with translational research components. During Years 20-24, UNC will again commit $200,000 annually to developmental clinical, translational breast cancer research projects. We request $100,000 in SPORE funds to combine with $100,000 in institutional commitment to fund approximately three to four projects per year at $25,000 to $100,000/year. During the last SPORE cycle, institutional funding averaged $200,000 yearly, doubling our stated commitment.

现在，第20年，UNC乳腺癌孢子的发育研究计划（DRP）继续促进新颖的乳腺癌研究。该计划包括刺激赠款应用程序，评估建议，选择项目和监视进度的机制。博士。 Lisa Carey和Charles Perou是UNC Lineberger的乳腺癌研究计划的总体联合指导和领导者，负责监督DRP机制，以识别，评估，选择和监测。应用机制包括癌症中心竞争性奖项和迅速新兴的机会。评估和选择过程包括独立的同行审查和与孢子执行委员会以及高级领导和外部顾问（包括拥护者）的咨询。 Spore主管/PI（EARP博士），共同导演/Co-Pis（Carey，Perou）和执行委员会的意见做出了有关选择和预算的最终决定。 DRP继续有效。在过去的六年中（14-19年），该计划资助了17个项目，自1992年的孢子开始以来，将总数达到61个项目。与过去的几年一样，DRP项目导致了成熟的孢子项目和独立资助的项目以及出版物。例如，在过去四年中提出的五年级孢子支持的五个项目中，有三个涉及DRP项目：（1）项目5（约翰逊，EARP）正在基于DRP Project＃54（Johnson）； （2）项目4（TROESTER，AMOS）直接从DRP项目＃53（TORESTER）中生长； （3）项目2（血清，dees）是通过DRF项目＃51（血清）开发的。此外。项目1（Millikan，Carey，Lin）和3（Carey，Carey）最初是基于早期周期中DRP的工作。 在过去六年中支持的17个DRP项目中，有6个刚刚开始。在还有十一个成熟的项目中，所有这些项目都随着出版物，完整的项目或壁外资金而进展。十个获得了校外资金（包括三个NCI R01，两个NCI K23，两个Komen Grants，一项DOD Idea Award，一个Niehs U01和一个赢得癌症奖）。八个项目制作了出版物，三个项目支持通过转化研究组件开发临床试验。 在20 - 24年期间，UNC每年将每年再次投入200,000美元用于发展性临床乳腺癌研究项目。我们要求$ 100,000的孢子资金与$ 100,000的机构承诺相结合，每年为大约3到四个项目提供25,000美元至100,000美元/年的资金。在最后一个孢子周期中，机构资金平均每年为20万美元，使我们陈述的承诺增加了一倍。